{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":20,"n_cols":5,"rows_kept":20,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[13,2,13,3],[14,2,14,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910409693003321"]
[null,null,"Titolo",null,"Substance Use Disorders : From Etiology to Treatment / / edited by Michael A. Nader, Yasmin L. Hurd"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020"]
[null,null,"ISBN",null,"3-030-33679-4"]
[null,null,"Edizione",null,"[1st ed. 2020.]"]
[null,null,"Descrizione fisica",null,"1 online resource (x, 502 pages)"]
[null,null,"Collana",null,"Handbook of Experimental Pharmacology, , 1865-0325 ; ; 258"]
[null,null,"Disciplina",null,"616.86"]
[null,null,"Soggetti",null,"Pharmacology"]
[{"$nulls":4},"Malalties mentals"]
[{"$nulls":4},"Farmacologia"]
[{"$nulls":4},"Drogues"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"1. Methods for Population Research on Substance Use and Consequences -- 2. Translational Molecular Approaches in Substance Abuse Research -- 3. Small Molecule Neuropeptide-S and Melanocortin Receptor Ligands As Potential Treatments for Substance Use Disorders -- 4. Emerging Insights into Mu Opioid Pharmacology -- 5. Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors -- 6. The Rise and Fall of Kappa-Opioid Receptors in Drug Abuse Research -- 7. Clinical Trials for Opioid Use Disorder -- 8. Modelling Differential Vulnerability to Substance Use Disorder in Rodents: Neurobiological Mechanisms -- 9. Activity-Dependent Epigenetic Remodeling in Cocaine Use Disorder -- 10. Molecular Mechanisms of Amphetamines -- 11. Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes -- 12. Molecular Mechanism and Cannabinoid Pharmacology -- 13. Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents -- 14. Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence -- 15. Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade -- 16. Adolescent Vulnerability to Alcohol Use Disorder: Neurophysiological Mechanisms from Preclinical Studies -- 17. Medication Development for Alcohol Use Disorder: A Focus on "]
[{"$nulls":4},"Clinical Studies -- 18. Newly Emerging Drugs of Abuse."]
[null,null,null,"Sommario/riassunto","The purpose of this book is to provide a broad scope of substance use disorder research and how these findings can impact treatment outcomes. The research and outcomes described in this book represent important principles related to identifying and understanding factors related to substance use disorders. The first section is dedicated to methodology including population-based surveys, basic neuroanatomy, chemistry, molecular biology, behavioral models and brain imaging. The second section utilizes this methodology in research related to opioids, cocaine, marijuana, alcohol and nicotine. The book is aimed at both professionals (academics, clinicians, practitioners) and students or trainees."]